Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. - Pappalardi MB; Keenan K; Cockerill M; Kellner WA; Stowell A; Sherk C; Wong K; Pathuri S; Briand J; Steidel M; Chapman P; Groy A; et al. (Nature cancer, 2021)